Actuate Therapeutics ACTU

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.09 (-1.30%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Actuate Therapeutics (ACTU)
    Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $6.95

    • Market Cap

      $135.74 Million

    • Price-Earnings Ratio

      -12.64

    • Total Outstanding Shares

      19.53 Million Shares

    • Dividend

      No dividend

    • IPO Date

      August 13, 2024

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      1751 river run, Fort worth, TX, 76107

    • Homepage

      https://www.actuatetherapeutics.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Cash Flow$0
    Net Cash Flow, Continuing$0
    Net Cash Flow From Operating Activities$-9.15 Million
    Net Cash Flow From Investing Activities$-13.17 Million
    Net Cash Flow From Financing Activities$22.32 Million
    Net Cash Flow From Financing Activities, Continuing$22.32 Million

    Income Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Basic Earnings Per Share$-0.55
    Diluted Earnings Per Share$-0.55
    Net Income/Loss Available To Common Stockholders, Basic$-5.97 Million
    Income/Loss From Continuing Operations After Tax$-5.97 Million
    Revenues$0
    Research and Development$3.76 Million

    Comprehensive Income

    July 1, 2024 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss$-5.97 Million
    Comprehensive Income/Loss Attributable To Parent$-5.97 Million
    Other Comprehensive Income/Loss$0
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

    Balance Sheet

    July 1, 2024 to September 30, 2024
    MetricValue
    Temporary Equity$0
    Noncurrent Liabilities$406,683
    Accounts Payable$2.33 Million
    Liabilities$8.90 Million
    Noncurrent Assets$0
    Other Current Liabilities$6.17 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ACTU from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.